Healthcare Industry News: UCB
News Release - October 22, 2012
Osiris Therapeutics Names Lode Debrabandere Chief Operating OfficerCOLUMBIA, Md.--(Healthcare Sales & Marketing Network)--Osiris Therapeutics, Inc. (OSIR) announced today it has promoted Lode Debrabandere, Ph.D. to the role of Chief Operating Officer (COO) reporting directly to Chief Executive Officer, C. Randal Mills, Ph.D. Dr. Debrabandere has been with Osiris since 2006 in various leadership positions, most recently serving as Senior Vice President for Therapeutics. During his time at Osiris, Dr. Debrabandere has played a key role in the development and approval of Osiris’ products including Prochymal® (remestemcel-L), which earlier this year became the world’s first stem cell drug to be granted marketing approval by an internationally recognized regulatory authority.
"This is an exciting time at Osiris as we move rapidly into the commercialization of stem cell medicine," said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. "Over the past six years, Lode has proven to be an effective leader and his unique skill set will become increasingly more important at Osiris as we move forward."
Prior to joining Osiris, Dr. Debrabandere served as Vice President of Global Marketing with Bristol-Myers Squibb where he was the Global Brand Leader for Abilify®. Previously, Dr. Debrabandere led the Marketing department of UCB Pharma, Inc., focusing in the areas of allergy (Zyrtec™) and neurology (Keppra™). Prior to that, he was the Head of worldwide clinical operations at UCB Pharma, Inc. Dr. Debrabandere earned an M.B.A., a Ph.D. in toxicology and a Pharm. D. degree, all from the University of Leuven, Belgium.
About Osiris Therapeutics
Osiris Therapeutics, Inc., having developed the world’s first approved stem cell drug, Prochymal, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. In Biosurgery, Osiris currently markets Grafix® for burns and chronic wounds, and Ovation® for orthopedic applications. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology, including 48 U.S. and 144 foreign patents.
Osiris, Prochymal, Grafix and Ovation are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company's website, www.Osiris.com.
This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for mesenchymal stem cells and biologic drug candidates and marketed Biosurgery products (including Prochymal®, ChondrogenTM, Grafix® and Ovation®); our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to treat disease; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available, products to meet demand; our costs to comply with governmental regulations; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; and results of our scientific research. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled "Risk Factors" in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.
Source: Osiris Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.